
Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

Your AI-Trained Oncology Knowledge Connection!


Published: May 9th 2016 | Updated: